

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Oncologic Drugs Advisory Committee (ODAC) Meeting
Tommy Douglas Conference Center
10000 New Hampshire Avenue, Silver Spring, Maryland 20903
September 14, 2016

MEETING ROSTER

DESIGNATED FEDERAL OFFICER (Non-Voting)

Lauren D. Tesh, PharmD, BCPS

Division of Advisory Committee and Consultant Management
Office of Executive Programs, CDER, FDA
Silver Spring, Maryland

ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBERS (Voting)

Bernard F. Cole, PhD

Professor
Department of Mathematics and Statistics
University of Vermont
Burlington, Vermont

Grzegorz S. Nowakowski, MD

Assistant Professor of Medicine
Mayo Clinic Rochester
Rochester, Minnesota

Vassiliki Papadimitrakopoulou, MD

Professor of Medicine
Thoracic/Head and Neck Medical Oncology
MD Anderson Cancer Center
Houston, Texas

Gregory J. Riely, MD, PhD

Associate Attending
Memorial Sloan Kettering Cancer Center
Associate Professor, Weill Cornell Medical College
New York, New York

Brian I. Rini, MD, FACP

Professor of Medicine
Cleveland Clinic Taussig Cancer Institute
Glickman Urological and Kidney Institute
Cleveland, Ohio

Bruce J. Roth, MD

(Chairperson)
Professor of Medicine
Division of Oncology
Washington University School of Medicine
St. Louis, Missouri

Thomas S. Uldrick, MD, MS

Clinical Director
HIV & AIDS Malignancy Branch, Center for Cancer
Research
National Cancer Institute
Bethesda, Maryland

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Oncologic Drugs Advisory Committee (ODAC) Meeting
September 14, 2016

MEETING ROSTER (cont.)

ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBER (Non-Voting)

Phuong Khanh (P.K.) Morrow, MD, FACP

(Industry Representative)

Executive Medical Director, Amgen Oncology
Therapeutic Area Head, US Medical Organization
Thousand Oaks, California

TEMPORARY MEMBERS (Voting)

Karim Chamie, MD, MSHS

Assistant Professor of Urology
Department of Urology
University of California, Los Angeles
Los Angeles, California

Mark L. Gonzalgo, MD, PhD

Professor
Department of Urology
University of Miami Miller School of Medicine
Miami, Florida

Pamela J. Haylock, PhD, RN

(Acting Consumer Representative)
Adjunct Faculty, Sul Ross State University
Alpine, Texas
Oncology Nursing Educator
Medina, Texas

Brent Logan, PhD

Professor and Director
Division of Biostatistics
Medical College of Wisconsin
Milwaukee, Wisconsin

Patricia A. Spears

(Patient Representative)
Raleigh, North Carolina

Jennifer M. Taylor, MD, MPH

Assistant Professor, Urology
Baylor College of Medicine
Michael E. DeBakey VA Medical Center
Houston, Texas

John A. Taylor, III, MD, MS

Professor of Urology
Co-Director, Drug Development Discovery &
Experimental Therapeutics
University of Kansas Medical Center
Kansas City, Kansas

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Oncologic Drugs Advisory Committee (ODAC) Meeting
September 14, 2016

MEETING ROSTER (cont.)

FDA PARTICIPANTS (Non-Voting)

Richard Pazdur, MD

Acting Director, Oncology Center of Excellence
(OCE), FDA
Director, Office of Hematology and Oncology
Products (OHOP)
Office of New Drugs (OND), CDER, FDA

Geoffrey Kim, MD

Director
Division of Oncology Products 1 (DOP1)
OHOP, OND, CDER, FDA

Ellen Maher, MD

Medical Team Leader
Genitourinary Cancers Team
DOP1, OHOP, OND, CDER, FDA

Gwynn Ison, MD

Medical Officer
DOP1, OHOP, OND, CDER, FDA

Chana Weinstock, MD

Medical Officer
Genitourinary Cancers Team
DOP1, OHOP, OND, CDER, FDA

Erik Bloomquist, PhD

Statistical Reviewer
Division of Biometrics V (DBV)
Office of Biometrics (OB)
Office of Translational Sciences (OTS)
CDER, FDA